|
|
|
|
|
|
|
|
|
|
YouTube
Published on Aug 2, 2016
Prof
Ledermann talks to ecancertv at ASCO 2016 about the updated survival
data associated with the PARP inhibitor olaparib in a certain subset of
ovarian cancer patients.
He also highlights the novel exploratory endpoints that were used for the first time within an oncology trial (TFST and TSST), and highlights that 15% of patients entered into the study possessing mutant strains of BRCA are still receiving maintenance therapy 5 years later.
For future clinical use, it is important to establish precisely those patients who will benefit the most, due to the cost of the drug.
He also highlights the novel exploratory endpoints that were used for the first time within an oncology trial (TFST and TSST), and highlights that 15% of patients entered into the study possessing mutant strains of BRCA are still receiving maintenance therapy 5 years later.
For future clinical use, it is important to establish precisely those patients who will benefit the most, due to the cost of the drug.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.